Cibinetide
Description
Cibinetide (ARA290) is a non-hematopoietic Erythropoietin analog. Cibinetide selectively activates the EPOR/CD131 heteromer IRR without activating EPOR homodimers, and exerts neuroprotective effects through β-common receptor signaling. Cibinetide inhibits Cathepsin K/OSCAR/OC-STAMP/DC-STAMP/NFATC1, increases OPG and Alkaline phosphatase, and decreases CD115. Cibinetide modulates SIRT1/NF-??B/IL-1β signaling, reduces inflammatory infiltration and periapical bone loss, protects pancreatic islets, reduces IBMIR-related platelet consumption, and prolongs graft function. Cibinetide extends healthspan and attenuates age-related cardiac and body weight decline. Cibinetide can be used in research on cerebral ischemic stroke, sarcoidosis-associated small fiber neuropathy, and type 1 diabetes.
Product Information
| Product Name | Cibinetide |
| Molecular Weight | 1257.31 |
| Formula | C51H84N16O21 |
| CAS Number | 1208243-50-8 |
| Appearance | Solid |
| Color | White to off-white |
| Sequence | {Glp}-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| Sequence Shortening | {Glp}-EQLERALNSS |
| Storage | Sealed storage, away from moisture Powder -80??C 2 years -20??C 1 year *In solvent : -80??C, 6 months; -20??C, 1 month (sealed storage, away from moisture) |
